The Impact of Combined Vitamin D and A Supplementation on Clinical Outcomes in Patients with Pneumosepsis: A Randomized Double-Blind Clinical Trial Authors: Abolfazl Jokar, Alireza Sistani, Farshideh Didgar, Elham Niasati Published: 2026 ABSTRACT Background:Pneumosepsis is a severe and potentially life-threatening infection of the lower respiratory tract. This study aimed to investigate the effect of combined vitamin D and A supplementation on clinical outcomes in patients with pneumosepsis.Material and Methods:Eighty-four patients with pneumosepsis were randomly assigned to four groups in this double-blind clinical trial. Group 1 received standard treatment plus 300,000 IU intramuscular vitamin D and 50,000 IU intramuscular vitamin A. Group 2 received standard treatment plus 300,000 IU intramuscular vitamin D. Group 3 received standard treatment plus 50,000 IU intramuscular vitamin A. Group 4 received standard treatment only. Clinical parameters including ESR, CRP, creatinine, urea, and uric acid levels were recorded at baseline, 24, 48, and 72 hours after intervention.Results:The combined vitamin D and A group (Group 1) demonstrated significantly lower blood pressure, respiratory rate, heart rate, temperature, ESR, CRP, and white blood cell count compared to the other groups at all three time points.Conclusion:The study suggests that combined vitamin D and A supplementation, in addition to standard treatment, may improve clinical outcomes and potentially reduce the duration of hospitalization in patients with pneumosepsis. However, further research is warranted to confirm these findings and elucidate the underlying mechanisms.Trial Registration:This study is registered on Iranian Registry of Clinical Trials (IRCT) under the identifier IRCT20130424013110N10. (The registration date: July 6, 2020). INTRODUCTION Pneumosepsis, also known as severe pneumonia with sepsis, is a critical condition characterized by a severe infection of the lower respiratory tract that leads to systemic inflammation and organ dysfunction.[1] It is considered a medical emergency with high morbidity and mortality rates, necessitating prompt recognition and appropriate management. The importance of pneumosepsis lies in its detrimental impact on patient health and the healthcare system as a whole. It is a major cause of morbidity and mortality worldwide, particularly in vulnerable populations such as the elderly, immunocompromised individuals, and those with underlying comorbidities. The incidence of pneumosepsis has been rising in recent years, posing a significant burden on healthcare resources and necessitating effective management strategies.[2] The clinical symptoms of pneumosepsis can vary depending on the severity of the infection and the individual patient’s response. Common presenting features include high fever, rapid and shallow breathing, increased heart rate, low blood pressure, confusion or altered mental status, and signs of respiratory distress such as cough, chest pain, and difficulty breathing. Laboratory findings often reveal elevated inflammatory markers, such as C-reactive protein (CRP) and procalcitonin, along with abnormalities in blood gas analysis and complete blood count.[3] Early recognition and timely treatment of pneumosepsis are of paramount importance to improve patient outcomes.[4] The initial management involves the administration of broad-spectrum antibiotics to target the causative microorganisms until specific pathogen identification and susceptibility results are available. Supportive care, including adequate oxygenation, fluid resuscitation, and hemodynamic support, is crucial to maintain vital organ function. In severe cases, patients may require intensive care unit (ICU) admission and mechanical ventilation.[56] The significance of pneumosepsis lies not only in its clinical impact but also in the associated economic burden. The management of pneumosepsis requires substantial healthcare resources, including hospitalization, diagnostic tests, antimicrobial therapy, and supportive care. Moreover, survivors of pneumosepsis often experience long-term complications, such as cognitive impairment, functional decline, and reduced quality of life, which further contribute to the overall socioeconomic impact of the disease.[37] To address the challenges posed by pneumosepsis, ongoing research efforts are focused on improving early detection, refining diagnostic tools, developing targeted therapies, and enhancing supportive care strategies.[8] Promising avenues of investigation include the identification of biomarkers for early sepsis detection, the development of novel antimicrobials to combat multidrug-resistant pathogens, and the exploration of immunomodulatory therapies to modulate the dysregulated immune response observed in pneumosepsis.[79] By furthering our understanding of the pathophysiology, diagnostic approaches, and therapeutic interventions for pneumosepsis, we can strive to enhance patient care and ultimately save lives. One promising avenue of investigation is the combined supplementation of vitamin D and vitamin A. Both vitamins have been extensively studied for their immunomodulatory properties and their role in supporting respiratory health[10] Recent studies highlight the importance of vitamin D and A supplementation in strengthening the immune system of patients with infectious diseases and critically ill patients. Vitamin D improves the body’s defense by increasing the expression of antimicrobial peptides, such as cathelicidin and defensins, which are crucial for respiratory health. Deficiency in this vitamin has been associated with an increased risk of severe respiratory infections and critical conditions like sepsis.[11] Vitamin A also plays a vital role in maintaining respiratory epithelial integrity and enhancing mucosal immunity; its deficiency is linked to a higher risk of respiratory infections and adverse outcomes in critical care patients. Combined supplementation of these two vitamins has been shown to reduce infection severity and shorten hospitalization duration in septic patients.[1213] Several observational studies have found an association between low vitamin D levels and an increased risk of respiratory infections.[1415] Adequate vitamin D levels are protective against upper respiratory tract infections, including the common cold. Higher vitamin D status has also been associated with a reduced risk of influenza.[16] Vitamin D also regulates the expression of genes involved in the immune response, enhancing the body’s ability to fight off infections. It promotes the production of antimicrobial peptides, such as cathelicidin and defensins, which play a crucial role in combating respiratory pathogens. Vitamin D has been shown to enhance the immune response and reduce the risk of respiratory infections, while vitamin A plays a crucial role in maintaining the integrity of respiratory epithelial cells and mucosal barriers.[17] It supports the integrity of mucosal surfaces in the respiratory tract, which act as a physical barrier against pathogens. Vitamin A also plays a role in the differentiation and activation of immune cells, such as T cells and B cells, thereby promoting an effective immune response against respiratory infections. Other studies suggested that adequate vitamin A status has been associated with a decreased susceptibility to respiratory infections, including pneumonia and measles, particularly in children. Vitamin A deficiency is known to impair the immune response, making individuals more susceptible to infections. Supplementation with vitamin A has been shown to reduce the risk and severity of respiratory infections, especially in populations with vitamin A deficiency.[1819] However, the impact of combined vitamin D and A supplementation on clinical outcomes in patients with pneumosepsis has not been thoroughly investigated. Therefore, this study aims to fill this knowledge gap by conducting a randomized double-blind clinical trial to assess the effects of combined vitamin D and A supplementation on clinical parameters and duration of hospitalization in patients with pneumosepsis. By elucidating the potential benefits of combined vitamin D and A supplementation, this research has the potential to contribute to the development of novel therapeutic approaches for pneumosepsis management. MATERIALS AND METHODS Study design, registrations, and patient consent Our study employed a randomized controlled trial design to assess the efficacy of supplemental vitamin D and vitamin A in conjunction with standard treatment for patients diagnosed with pneumosepsis. Patients meeting the specified inclusion criteria were randomly allocated to one of four groups. Vital signs and laboratory parameters were monitored at regular intervals throughout the study period. The trial protocol was registered with a recognized clinical trial registry before patient recruitment. All relevant details of the study design, interventions, and outcome measures were registered to ensure transparency and adherence to ethical standards (Iranian Registry of Clinical Trials (IRCT) under identifier IRCT20130424013110N10. (The registration date: July 6, 2020). Before enrollment, written informed consent was obtained from each participant or their legal guardian after providing detailed information about the study objectives, procedures, potential risks, and benefits. Patients were assured of their right to withdraw from the study at any time without affecting their ongoing medical care. Confidentiality of personal information and data security measures were strictly maintained throughout the study duration. After collecting demographic data, electrocardiography, arterial oxygen saturation monitoring, venous or arterial blood sampling, and plain chest radiography, patients were randomly assigned by emergency medicine specialists using block randomization with block sizes of eight to different groups. Participant selection Patients diagnosed with pneumosepsis, defined as the presence of a respiratory tract infection and meeting at least two of the following criteria (T>38°C or <36°C, heart rate >90 beats per minute, respiratory rate >24 breaths per minute, white blood cell count 4000–12000 or bandemia >10%), as well as varying degrees of organ failure. Patients were recruited from Valiasr, Amiralmomenin, and Khansari hospitals in Arak after obtaining written consent. Upon meeting the inclusion and exclusion criteria, they were enrolled in the study. Inclusion criteria were as follows: Age >18 years and diagnosis of pneumosepsis. Exclusion criteria were serum calcium level ≥10, receipt of vitamin D supplementation within the past 3 months, receipt of vitamin A supplementation within the past 3 months, history of liver failure, parathyroid disorders, metabolic bone diseases, sarcoidosis, or end-stage renal disease (ESRD) as per patient medical history, imminent risk of mortality, pregnancy, and lack of consent to participate in the study. Randomization and intervention protocol 1-Patient allocationFollowing the collection of demographic information, electrocardiography, registration of vital signs including arterial oxygen saturation, venous or arterial blood sampling, and plain chest radiography, patients were allocated to different treatment groups through block randomization. This allocation was overseen by emergency medicine specialists using block sizes of eight to assign individuals to the respective study groups.2-Treatment regimens:Group 1: Patients in this group received standard treatment along with intramuscular administration of 300,000 IU of vitamin D (in a volume of 1 ml) and 50,000 IU of vitamin A (in a volume of 1 ml).Group 2: In addition to standard treatment, patients in this group received intramuscular administration of 300,000 IU of vitamin D.Group 3: In addition to standard treatment, patients in this group received intramuscular administration of 50,000 IU of vitamin A (in a volume of 1 ml).Group 4: Patients in this group received only standard treatment.3-Monitoring:The vital signs of patients were monitored every 6 hours. Additionally, laboratory parameters including WBC, ESR, CRP, creatinine, urea, and uric acid levels were recorded at baseline (time zero), 24, 48, and 72 hours post-treatment initiation. The duration of hospitalization in different wards, categorized by ward, and the mortality rate were also documented. 1-Patient allocation 1-Patient allocation Following the collection of demographic information, electrocardiography, registration of vital signs including arterial oxygen saturation, venous or arterial blood sampling, and plain chest radiography, patients were allocated to different treatment groups through block randomization. This allocation was overseen by emergency medicine specialists using block sizes of eight to assign individuals to the respective study groups. Following the collection of demographic information, electrocardiography, registration of vital signs including arterial oxygen saturation, venous or arterial blood sampling, and plain chest radiography, patients were allocated to different treatment groups through block randomization. This allocation was overseen by emergency medicine specialists using block sizes of eight to assign individuals to the respective study groups. 2-Treatment regimens:Group 1: Patients in this group received standard treatment along with intramuscular administration of 300,000 IU of vitamin D (in a volume of 1 ml) and 50,000 IU of vitamin A (in a volume of 1 ml).Group 2: In addition to standard treatment, patients in this group received intramuscular administration of 300,000 IU of vitamin D.Group 3: In addition to standard treatment, patients in this group received intramuscular administration of 50,000 IU of vitamin A (in a volume of 1 ml).Group 4: Patients in this group received only standard treatment. 2-Treatment regimens: Group 1: Patients in this group received standard treatment along with intramuscular administration of 300,000 IU of vitamin D (in a volume of 1 ml) and 50,000 IU of vitamin A (in a volume of 1 ml). Group 1: Patients in this group received standard treatment along with intramuscular administration of 300,000 IU of vitamin D (in a volume of 1 ml) and 50,000 IU of vitamin A (in a volume of 1 ml). Group 2: In addition to standard treatment, patients in this group received intramuscular administration of 300,000 IU of vitamin D. Group 2: In addition to standard treatment, patients in this group received intramuscular administration of 300,000 IU of vitamin D. Group 3: In addition to standard treatment, patients in this group received intramuscular administration of 50,000 IU of vitamin A (in a volume of 1 ml). Group 3: In addition to standard treatment, patients in this group received intramuscular administration of 50,000 IU of vitamin A (in a volume of 1 ml). Group 4: Patients in this group received only standard treatment. Group 4: Patients in this group received only standard treatment. 3-Monitoring: 3-Monitoring: The vital signs of patients were monitored every 6 hours. Additionally, laboratory parameters including WBC, ESR, CRP, creatinine, urea, and uric acid levels were recorded at baseline (time zero), 24, 48, and 72 hours post-treatment initiation. The duration of hospitalization in different wards, categorized by ward, and the mortality rate were also documented. The vital signs of patients were monitored every 6 hours. Additionally, laboratory parameters including WBC, ESR, CRP, creatinine, urea, and uric acid levels were recorded at baseline (time zero), 24, 48, and 72 hours post-treatment initiation. The duration of hospitalization in different wards, categorized by ward, and the mortality rate were also documented. Statistical analysis Statistical analysis was performed using SPSS software ver. 20, including One-way ANOVA, Bonferroni or Tukey’s honestly significant difference (HSD) repeated measures analysis of variance and other appropriate tests. RESULTS The present study aimed to investigate the effect of simultaneous administration of vitamin D and A on the symptoms of patients with pneumosepsis. A total of 84 individuals were enrolled in the study, with 22 participants assigned to the group receiving simultaneous vitamin A and D supplementation, 20 participants allocated to the group receiving vitamin D alone, 21 participants assigned to the group receiving vitamin A alone, and finally, 21 participants included in the control group [Figure 1]. CONSORT (Consolidated standards of reporting trials) Clinical outcomes The results of the present study indicated that there were no statistically significant differences in demographic variables among the different groups [Table 1]. Regarding systolic blood pressure, no statistically significant differences were observed among the three groups at baseline, one day, and two days post-intervention. However, on the third day post-intervention, the intervention group receiving the combination of vitamin D and A showed significantly lower diastolic blood pressure compared to the other groups To ensure consistency and control for dietary influences on clinical parameters, including blood pressure, all participants across the four groups received a standardized diet throughout the study period. This approach was implemented to reduce variability and ensure that any observed effects could be more confidently attributed to the vitamin D and A supplementation [Table 1]. Table 1Vital signs of patients with pneumosepsis were allocated to four groupsGroupAge (years)Height (CM)Weight (Kg)Systolic blood pressure Mean (mmHg)Diastolic blood pressure (mmHg)Breathing rate (Breaths per minute)Heartbeat rate MeanTemperature (C°) 02448720244872024487202448720244872Intervention A,D63.49±10.78164.65±7.8274.18±10.9213.212.9513.211.56.76.746.85.526.2922.7818.518.14101.7299.1379.1278.8538.8738.7437.2437.14Intervention D64.51±22.11158.13±9.8275.18±11.1013.213.1513.213.56.56.326.696.4929.8922.924.2520.4798.54102.3685.7284.6538.6838.8438.638.2Intervention A61.14±11.33164.65±7.8274.18±10.9213.513.213.513.56.76.456.576.556.622.7824.0520.299.1298.4370.4188.6338.7538.838.538.3Control61.49±7.25160.65±10.1813.9±18.8013.513.313.613.56.656.46.76.5526.5522.824.2520.35100.7497.3398.6981.13738.8338.4338.8 P >0.5>0.5>0.5>0.11>0.89>0.9>0.8>0.85>0.68>0.65>0.002>0.68>0.33>0.001>0.001>0.41>0.8>0.04>0.03>0.85>0.95>0.002>0.005 Vital signs of patients with pneumosepsis were allocated to four groups Similarly, there were no statistically significant differences in respiratory rate among the three groups at baseline and one day post-intervention. However, on the second and third days post-intervention, the intervention group receiving the combination of vitamin D and A demonstrated significantly lower respiratory rates compared to the other groups [Table 1]. Regarding heart rate, no statistically significant differences were reported among the three groups at baseline and one day post-intervention. However, on the second and third days post-intervention, the intervention group receiving the combination of vitamin D and A exhibited significantly lower heart rates compared to the other groups [Table 1]. There were no statistically significant differences in temperature among the three groups at baseline and one-day post-intervention. However, on the second and third days post-intervention, the intervention group receiving the combination of vitamin D and A showed significantly lower temperatures compared to the other groups [Table 1]. No statistically significant differences in white blood cell count were observed among the three groups at baseline, one day, and two days post-intervention. However, on the third day post-intervention, the intervention group receiving the combination of vitamin D and A demonstrated significantly lower white blood cell counts compared to the other groups [Table 2]. Table 2Laboratory parameters of patients with pneumosepsis were allocated to four groupsGroupAge (years)Height (CM)Weight (Kg)WBC (cells/mm3)BUN (mg/dL)Creatinine (mg/dL)ESR (mm/hr)*1CRP (mg/dL) 02448720244872024487202448720244872Intervention A,D63.49±10.78164.65±7.8274.18±10.9215.3713.7212.0910.4256.6153.3733.5528.242.622.282.21.425.9125.919.5418.192.622.281.91.56Intervention D64.51±22.11158.13±9.8275.18±11.1015.8414.2213.1314/1459.6752/5233.0825.292.3121.982.226.2625.824.2612.552.3122.22.56Intervention A61.14±11.33164.65±7.8274.18±10.9215.5514.813.8515.2553.750.6630.328.242.32.21.862.226.426.2424.5625.782.32.12.32.45Control61.49±7.25160.65±10.1813.9±18.8015.5715.1514.3515.1654.6553.5133.830.22.42.32.31.991/2724.222.126.652.42.222.92.55 P >0.5>0.5>0.5>0.89>0.86>0.66>0.002>0.55>0.66>0.45>0.004>0.56>0.96>0.47>0.006>0.56>0.65>0.003>0.006>0.11>0.11>0.11>0.11Reference value 0–20 mm/h for men and 0–30 mm/h for women Laboratory parameters of patients with pneumosepsis were allocated to four groups Reference value 0–20 mm/h for men and 0–30 mm/h for women Similarly, no statistically significant differences in BUN and creatinine levels were reported among the three groups at baseline and one day post-intervention. However, on the third day post-intervention, the intervention group receiving the combination of vitamin D and A showed significantly lower BUN and creatinine levels compared to the other groups [Table 2]. Regarding ESR and CRP, no statistically significant differences were observed among the three groups at baseline and one day post-intervention. However, on the second and third days post-intervention, the intervention group receiving the combination of vitamin D and A demonstrated significantly lower ESR and CRP levels compared to the other groups [Table 2]. Other parameters Data analysis of the duration of hospitalization of patients demonstrated that this parameter was lower among intervention group 1 than group 2, 3, and control, respectively [Figure 2]. Chart of average duration of hospitalization of patients in different groups DISCUSSION Pneumosepsis, a severe form of sepsis caused by Streptococcus pneumonia, represents a significant health concern both in Iran and globally. In Iran, the incidence of sepsis, including pneumosepsis, has been reported to range between 10-20% of all sepsis cases, with pneumonia being one of the most common sources.[20] Worldwide, pneumosepsis accounts for a large proportion of sepsis cases, with the global incidence estimated to be around 1–2 million cases annually. The morbidity rate associated with pneumosepsis remains high, with patients often experiencing prolonged hospital stays, severe organ dysfunction, and long-term sequelae. The mortality rate for pneumosepsis varies, but it remains a leading cause of death in critically ill patients, with mortality rates ranging from 25% to 50%, depending on factors such as the patient’s underlying health condition, timely intervention, and the presence of antimicrobial resistance.[21] Despite advances in medical care, pneumosepsis continues to pose a significant challenge to healthcare systems worldwide. Nowadays, we know that vitamins play a crucial role in completing the chain of the immune system.[22] Given the immunomodulatory properties of vitamin D and A, In this study, we aimed to explore their impact on clinical outcomes among patients diagnosed with pneumosepsis. Vitamin A is among the fat-soluble vitamins that can contribute to improving the innate immune system and its importance for overall health is undeniable. It exists in three forms: retinol, retinal, and retinoic acid. If the serum level of vitamin A in the blood plasma and liver decreases, it can lead to neurological disorders, vision problems, skin issues, immune system impairments, and reproductive problems.[2324] The consumption of vitamin A facilitates the function of the thymus gland, which plays a vital role in the immune system, meaning that this vitamin helps regulate thymocyte apoptosis. It also stimulates antibody secretion from B lymphocytes and activates various types of T-helper cells to combat foreign pathogens and disease-causing agents.[25] A study conducted in 2018 confirmed this theory. Huang et al.[26] reported that vitamin A regulates the population of bone marrow stromal cells by binding to retinoic acid receptors (RAR) in the nucleus of these cells. This binding alters the expression level of apoptosis-related genes such as Bcl-2, Fas, and others. However, the theory that vitamin A triggers this process is still a subject of debate. In 2016, Wynn et al.[27] found that retinoic acid plays a crucial role in regulating the differentiation, maturation, and function of innate immune cells. Innate immune cells, including macrophages and neutrophils, provide immediate responses to pathogen attacks through phagocytosis and activation of killer T cells, thereby influencing an individual’s immune system. In a study conducted by Ghodratizadeh et al.[28] on rabbits, it was concluded that supplements containing vitamin A can increase the serum levels of IgG, IgM, and IgA, thus enhancing humoral immunity. This finding confirms the results of our current study, indicating that vitamin A has a significant impact not only on humoral immune systems but also on cellular immune systems. Vitamin D, another fat-soluble vitamin, rapidly converts to active metabolites, vitamin D: 1,25-dihydroxy vitamin D3, in the liver. It promotes the intestinal absorption of calcium and phosphorus, the reabsorption of calcium from bones, and possibly the renal reabsorption of calcium.[23] Verstuyf et al.[29] reported that vitamin D increases the stimulation of immune cells, including activated CD4+ and CD8+ cells, B cells, neutrophils, and antigen-presenting cells (APCs) such as macrophages and dendritic cells (DCs). Increased stimulation of these cells leads to enhanced immune system activation against microorganisms, and the clinical results of our study support this report. In a study conducted by Ganguly et al.[30] in 2018, it was reported that vitamin D plays an important role in the phagocytosis of macrophages. There are vitamin D receptors on the surface of macrophages that significantly aid in the recognition of microorganisms by macrophages. These receptors are crucial, as the absence of these receptors disrupts the ability of macrophages to identify microorganisms, and our study confirms these findings. In a study by Sun et al.[31] in 2014, it was concluded that there are receptors for vitamin D in memory B lymphocytes, and vitamin D contributes to the enhancement of the immune system by strengthening memory B lymphocytes. Anand et al.[32] reported that vitamin A and vitamin D play a role in enhancing the immune system by activating and proliferating lymphocytes, differentiating T-helper cells, and producing specific isotypes of antibodies. This study also recommended the simultaneous consumption of vitamin A and vitamin D for the prevention of infections, sepsis, and autoimmune diseases. In overal, these studies in accordance with results of our study, found that vitamin D plays a crucial role in the proper functioning of the immune system, so vitamin D deficiency leads to increased susceptibility to severe infections and mortality in critically ill patients. The results of our study revealed noteworthy differences among the groups, with group 1, receiving combined vitamin D and A supplementation, demonstrating significantly lower blood pressure, respiratory rate, heart rate, temperature, ESR, CRP levels, and white blood cell count compared to the other groups across all three-time points. This mechanism is attributed to the synergistic effects of both vitamins in immune modulation, inflammation reduction, and autonomic regulation. Vitamin D decreases systemic inflammation by suppressing the production of pro-inflammatory cytokines such as IL-6 and TNF-α and enhancing anti-inflammatory cytokines like IL-10, which leads to lower ESR, CRP, and white blood cell counts.[33] Additionally, vitamin D regulates the renin-angiotensin-aldosterone system, improving endothelial function and reducing blood pressure. Vitamin A, through its antioxidant properties and inhibition of the NF-κB pathway, further supports immune regulation and inflammation control. The combined effects of these vitamins likely contributed to a reduction in heart rate and respiratory rate by modulating autonomic nervous system function. Furthermore, the anti-inflammatory effects of both vitamins likely aided in the normalization of body temperature. Overall, the synergistic mechanisms of vitamin D and A supplementation led to improved physiological parameters and better clinical outcomes in group 1.[34] Moreover, our results showed creatinine levels were risen in two intervention groups 2 and 3, and were dropped in group 1 in comparison with the control group. the observed differences in creatinine levels across the intervention groups may be attributed to the distinct effects of vitamin D and A, either separately or in combination, on renal function and inflammation in pneumosepsis. In groups 2 and 3, which received only vitamin D or vitamin A, the slight increase in creatinine levels might reflect an inflammatory or renal stress response, possibly because these vitamins alone may not fully counteract the underlying inflammatory processes impacting renal function. In contrast, group 1, which received both vitamins, showed a decrease in creatinine levels, suggesting a potential synergistic effect of combined supplementation in mitigating renal stress. This reduction may indicate an enhanced anti-inflammatory effect and improved renal function, likely due to the combined immunomodulatory and protective properties of both vitamins, as supported by their roles in reducing oxidative stress and inflammation. The results of this study align with the findings of other studies that indicate the individual and combined effects of vitamins D and A in providing anti-inflammatory and protective benefits for kidney function in inflammatory conditions. Consistent with previous research, our study also found that the combined supplementation of both vitamins led to a reduction in creatinine levels and an improvement in kidney function in the group receiving both vitamins. These findings are in line with studies such as Rapa et al. (2019) and Huang et al. (2023), which demonstrated that vitamins D and A can synergistically exert anti-inflammatory effects and protect against kidney injury in inflammatory states like sepsis.[3536] The findings of our study highlight the potential benefits of combined vitamin D and A supplementation as an adjunctive treatment in pneumosepsis management. Patients who received both vitamins showed significant improvements in clinical parameters, including reductions in blood pressure, respiratory rate, heart rate, temperature, ESR, CRP, and white blood cell count. These effects suggest that the vitamins may play a role in modulating the inflammatory response, potentially aiding in faster recovery and reducing the severity of the infection. Such improvements in critical clinical indicators not only support the potential of combined vitamin supplementation to improve patient outcomes but also open avenues for future research to explore its broader therapeutic applications in critical care settings. While our study provides valuable insights into the potential benefits of combined vitamin D and A supplementation in managing pneumosepsis, several limitations should be acknowledged. This study’s limitations include its single-center design, which may restrict the generalizability of findings and a relatively small sample size that limits the ability to detect subtle effects of vitamin D and A supplementation. Potential biases, such as selection bias and variations in patient adherence to treatment, may also have influenced results. To address these issues, future studies should include larger, multicenter trials to enhance applicability and explore optimal dosing regimens. Additionally, research into the specific immune pathways affected by these vitamins in pneumosepsis could lead to more targeted supplementation strategies in critical care settings. CONCLUSION In conclusion, our study investigated the impact of combined vitamin D and A supplementation on clinical outcomes in patients with pneumosepsis. The results showed that the group receiving both vitamins exhibited notable improvements in various clinical parameters such as blood pressure, respiratory rate, heart rate, temperature, ESR, CRP, and white blood cell count compared to the other groups. These findings suggest that the combination of vitamin D and A supplementation may have beneficial effects in managing pneumosepsis, highlighting the potential for further exploration and clinical application of such interventions in similar contexts. Ethical approval and consent to participate The current study was approved by the ethics committee of Arak University of Medical Sciences (Ethical code: IR.ARAKMU.REC.1399.180) under which the private and public daycares or nurseries are organized and operated. Any patient’s participant provided informed consent on their behalf. Consent for publication Not applicable Availability of data and material The data that support the findings of this study are available from the corresponding author upon reasonable request. Conflicts of interest There are no conflicts of interest.